JPMorgan Chase & Co. Trims UiPath (NYSE:PATH) Target Price to $19.00
UiPath (NYSE:PATH – Free Report) had its target price decreased by JPMorgan Chase & Co. from $28.00 to $19.00 in a report issued on Thursday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the healthcare company’s stock. Several other equities research analysts have also commented on the company. DA Davidson […]
More Stories
Biomea Fusion (NASDAQ:BMEA) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. I
Biomea Fusion (NASDAQ:BMEA – Get Free Report) was upgraded by equities research analysts at EF Hutton Acquisition Co. I to...
FY2025 Earnings Forecast for Lonza Group AG (OTCMKTS:LZAGY) Issued By William Blair
Lonza Group AG (OTCMKTS:LZAGY – Free Report) – Equities researchers at William Blair decreased their FY2025 earnings per share (EPS)...
JELD-WEN (NYSE:JELD) PT Raised to $17.00 at Jefferies Financial Group
JELD-WEN (NYSE:JELD – Get Free Report) had its price objective increased by investment analysts at Jefferies Financial Group from $15.00...
AON (NYSE:AON) Price Target Raised to $365.00
AON (NYSE:AON – Get Free Report) had its target price raised by investment analysts at Jefferies Financial Group from $344.00...
B. Riley Initiates Coverage on Uranium Royalty (NASDAQ:UROY)
B. Riley assumed coverage on shares of Uranium Royalty (NASDAQ:UROY – Free Report) in a report issued on Monday, Marketbeat.com...
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)
StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report issued on Tuesday morning. The...